Astellas Pharma Inc. - Net Worth and Insider Trading

Astellas Pharma Inc. Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Astellas Pharma Inc. owns 3 companies in total, including FibroGen Inc (FGEN) , Sucampo Pharmaceuticals Inc (SCMP) , and Taysha Gene Therapies Inc (TSHA) .

Click here to see the complete history of Astellas Pharma Inc.’s form 4 insider trades.

Insider Ownership Summary of Astellas Pharma Inc.

Ticker	Comapny	Transaction Date	Type of Owner
FGEN	FibroGen Inc	2014-11-13	10 percent owner
SCMP	Sucampo Pharmaceuticals Inc	2007-08-07	other: Former 10% Owner
TSHA	Taysha Gene Therapies Inc	2022-10-21	10 percent owner

Astellas Pharma Inc. Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Astellas Pharma Inc. Ownership Network

Ownership Network List of Astellas Pharma Inc.

No Data

Ownership Network Relation of Astellas Pharma Inc.

Astellas Pharma Inc. Owned Company Details

What does FibroGen Inc do?

Who are the key executives at FibroGen Inc?

Astellas Pharma Inc. is the 10 percent owner of FibroGen Inc. Other key executives at FibroGen Inc include Chief Commercial Officer Thane Wettig , director & Chief Executive Officer Enrique A Conterno , and SVP & China Operations Christine Chung .

FibroGen Inc (FGEN) Insider Trades Summary

Over the past 18 months, Astellas Pharma Inc. made no insider transaction in FibroGen Inc (FGEN). Other recent insider transactions involving FibroGen Inc (FGEN) include a net purchase of 29,738 shares made by Thane Wettig , a net sale of 92,477 shares made by Enrique A Conterno , and a net sale of 39,779 shares made by Christine Chung .

In summary, during the past 3 months, insiders sold 0 shares of FibroGen Inc (FGEN) in total and bought 50,000 shares, with a net purchase of 50,000 shares. During the past 18 months, 255,701 shares of FibroGen Inc (FGEN) were sold and 50,000 shares were bought by its insiders, resulting in a net sale of 205,701 shares.

FibroGen Inc (FGEN)'s detailed insider trading history can be found in Insider Trading Tracker table.

FibroGen Inc Insider Transactions

No Available Data

What does Sucampo Pharmaceuticals Inc do?

Who are the key executives at Sucampo Pharmaceuticals Inc?

Astellas Pharma Inc. is the other: Former 10% Owner of Sucampo Pharmaceuticals Inc. Other key executives at Sucampo Pharmaceuticals Inc include Chief Executive Officer Peter Greenleaf , CFO Peter P. Pfreundschuh , and Chief Science Officer Peter A Kiener .

Sucampo Pharmaceuticals Inc (SCMP) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Sucampo Pharmaceuticals Inc (SCMP) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Sucampo Pharmaceuticals Inc (SCMP) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Sucampo Pharmaceuticals Inc (SCMP)'s detailed insider trading history can be found in Insider Trading Tracker table.

Sucampo Pharmaceuticals Inc Insider Transactions

No Available Data

What does Taysha Gene Therapies Inc do?

Who are the key executives at Taysha Gene Therapies Inc?

Astellas Pharma Inc. is the 10 percent owner of Taysha Gene Therapies Inc. Other key executives at Taysha Gene Therapies Inc include director & 10 percent owner Paul B Manning , Chief Financial Officer Kamran Alam , and 10 percent owner Session R.a. Ii .

Taysha Gene Therapies Inc (TSHA) Insider Trades Summary

Over the past 18 months, Astellas Pharma Inc. made no insider transaction in Taysha Gene Therapies Inc (TSHA). Other recent insider transactions involving Taysha Gene Therapies Inc (TSHA) include a net sale of 549,095 shares made by Session R.a. Ii , a net purchase of 16,566,667 shares made by Paul B Manning , and a net purchase of 777,778 shares made by Stalfort John A Iii .

In summary, during the past 3 months, insiders sold 0 shares of Taysha Gene Therapies Inc (TSHA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 582,095 shares of Taysha Gene Therapies Inc (TSHA) were sold and 17,905,000 shares were bought by its insiders, resulting in a net purchase of 17,322,905 shares.

Taysha Gene Therapies Inc (TSHA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Taysha Gene Therapies Inc Insider Transactions

No Available Data

Astellas Pharma Inc. Mailing Address

Above is the net worth, insider trading, and ownership report for Astellas Pharma Inc.. You might contact Astellas Pharma Inc. via mailing address: 2-5-1, Nihonbashi-honcho, Chuo-ku, Tokyo M0 103-8411.

Discussions on Astellas Pharma Inc.

No discussions yet.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.